Archive: April, 2014

 

 

NEXVET ANNOUNCES US$31.5 MILLION FINANCING

Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage Capital Partners, L.P, Foresite Capital, and Tavistock Life Sciences subsidiary fund Boxer Capital, LLC, led the financing, which also included existing shareholders.

Read more about NEXVET ANNOUNCES US$31.5 MILLION FINANCING

Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014

Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014.

Read more about Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014

Avita Medical – ReCell receives FDA IDE Compassionate use approval.

ASX release here.

Read more about Avita Medical – ReCell receives FDA IDE Compassionate use approval.

Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe

Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and practical benefits to clinicians.

Read more about Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe

SeaDragon Investor Update March 2014

SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes:

 

Read more about SeaDragon Investor Update March 2014